AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
plazomicin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| aminoglycosides, antibiotics obtained from various Micromonospora | 5287 | 1154757-24-0 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
Plazomicin is an aminoglycoside that acts by binding to bacterial 30S ribosomal subunit, thereby inhibiting protein synthesis. Plazomicin has concentration-dependent bactericidal activity as measured by time kill studies. In vitro studies demonstrated a plazomicin post-antibiotic effect ranging from 0.2 to 2.6 hours at 2X MIC against Enterobacteriaceae.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
None
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| Vd (Volume of distribution) | 0.22 L/kg | Lombardo F, Berellini G, Obach RS |
| CL (Clearance) | 1.14 mL/min/kg | Lombardo F, Berellini G, Obach RS |
| fu (Fraction unbound in plasma) | 0.84 % | Lombardo F, Berellini G, Obach RS |
| t_half (Half-life) | 3.40 hours | Lombardo F, Berellini G, Obach RS |
| S (Water solubility) | 50 mg/mL | Bocci G, Oprea TI, Benet LZ |
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 3 | Bocci G, Oprea TI, Benet LZ |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | ACVR2B,BRAF,CAMK2D,CDK4,CDK5,EIF2AK3,GRK2,ITK,MAP2K6,MAPK10,MAPK7,NTRK1,NTRK2,PDK2,PDK4,PRKDC,TEK,TGFBR1,ZAP70 | 19 | |||
| kinase-selectivity-class | CHUK,IRAK4,MAP2K6,PDK1 | 4 | |||
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| June 25, 2018 | FDA | ACHAOGEN INC |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | J01GB14 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE AMINOGLYCOSIDE ANTIBACTERIALS Other aminoglycosides |
| CHEBI has role | CHEBI:33282 | antibacterial agent |
| CHEBI has role | CHEBI:35441 | antiinfective agent |
Related Drugs by ATC class:
J01GB Other aminoglycosides 12 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Urinary tract infectious disease | indication | 68566005 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 12.04 | acidic |
| pKa2 | 13.21 | acidic |
| pKa3 | 13.84 | acidic |
| pKa4 | 9.4 | Basic |
| pKa5 | 9.12 | Basic |
| pKa6 | 8.51 | Basic |
| pKa7 | 7.43 | Basic |
| pKa8 | 6.73 | Basic |
Orange Book patent data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
|---|---|---|---|---|---|---|---|---|---|---|
| EQ 500MG BASE/10ML (EQ 50MG BASE/ML) | ZEMDRI | CIPLA USA | N210303 | June 25, 2018 | DISCN | SOLUTION | INTRAVENOUS | 9266919 | Nov. 21, 2028 | METHOD OF USING PLAZOMICIN TO TREAT BACTERIAL INFECTIONS |
| EQ 500MG BASE/10ML (EQ 50MG BASE/ML) | ZEMDRI | CIPLA USA | N210303 | June 25, 2018 | DISCN | SOLUTION | INTRAVENOUS | 9688711 | Nov. 21, 2028 | METHOD OF USING PLAZOMICIN TO TREAT BACTERIAL INFECTIONS |
| EQ 500MG BASE/10ML (EQ 50MG BASE/ML) | ZEMDRI | CIPLA USA | N210303 | June 25, 2018 | DISCN | SOLUTION | INTRAVENOUS | 8383596 | June 25, 2032 | METHOD OF USING PLAZOMICIN TO TREAT BACTERIAL INFECTIONS |
Orange Book exclusivity data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
|---|---|---|---|---|---|---|---|---|---|
| EQ 500MG BASE/10ML (EQ 50MG BASE/ML) | ZEMDRI | CIPLA USA | N210303 | June 25, 2018 | DISCN | SOLUTION | INTRAVENOUS | June 25, 2023 | NEW CHEMICAL ENTITY |
| EQ 500MG BASE/10ML (EQ 50MG BASE/ML) | ZEMDRI | CIPLA USA | N210303 | June 25, 2018 | DISCN | SOLUTION | INTRAVENOUS | June 25, 2028 | GENERATING ANTIBIOTIC INCENTIVES NOW |
Bioactivity Summary:
None
External reference:
| ID | Source |
|---|---|
| LYO9XZ250J | UNII |
| 1380078-95-4 | SECONDARY_CAS_RN |
| 4037688 | VANDF |
| C3502652 | UMLSCUI |
| CHEBI:749946 | CHEBI |
| EDS | PDB_CHEM_ID |
| CHEMBL1650559 | ChEMBL_ID |
| 42613186 | PUBCHEM_CID |
| DB12615 | DRUGBANK_ID |
| CHEMBL2364623 | ChEMBL_ID |
| D10151 | KEGG_DRUG |
| 9522 | INN_ID |
| C550938 | MESH_SUPPLEMENTAL_RECORD_UI |
| 10847 | IUPHAR_LIGAND_ID |
| 1193790007 | SNOMEDCT_US |
| 725719004 | SNOMEDCT_US |
| 772052009 | SNOMEDCT_US |
| 34453 | MMSL |
| d08816 | MMSL |
| 017613 | NDDF |
| 017619 | NDDF |
| 2049549 | RXNORM |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Zemdri (plazomicin) | HUMAN PRESCRIPTION DRUG LABEL | 1 | 69097-820 | INJECTION | 500 mg | INTRAVENOUS | NDA | 30 sections |
| Zemdri (plazomicin) | HUMAN PRESCRIPTION DRUG LABEL | 1 | 71045-010 | INJECTION | 500 mg | INTRAVENOUS | NDA | 29 sections |
| Zemdri (plazomicin) | HUMAN PRESCRIPTION DRUG LABEL | 1 | 80735-820 | INJECTION | 500 mg | INTRAVENOUS | NDA | 30 sections |